Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Want to see OTLC full AI Analyst Report?
Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.04
▼(-56.25% Downside)
Action:ReiteratedDate:04/17/26
The score is held down primarily by weak financial performance (minimal revenue, persistent operating losses, and ongoing cash burn) and a bearish price trend below key moving averages. Corporate events provide some upside via pipeline/platform progress and partnerships, but the 2025 profit surge appears largely non-cash and valuation metrics provided do not offer clear support.
Positive Factors
Improved balance sheet
A materially stronger 2025 capital structure—very large equity versus modest debt—reduces near-term leverage risk and increases financial flexibility. This durable strengthening supports continued R&D, JV execution, and partnership negotiations without immediate reliance on dilutive financing.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicate the company cannot fund operations internally. Over the medium term this necessitates repeat external financing, constrains R&D pacing, and elevates execution risk for clinical programs absent sustainable cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet
A materially stronger 2025 capital structure—very large equity versus modest debt—reduces near-term leverage risk and increases financial flexibility. This durable strengthening supports continued R&D, JV execution, and partnership negotiations without immediate reliance on dilutive financing.
Read all positive factors
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.70M
Dividend YieldN/A
Average Volume (3M)410.07K
Price to Earnings (P/E)<0.1
Beta (1Y)-0.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.59
Shares Outstanding444,197,020
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap969.35K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.51M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase ...
How the Company Makes Money
null...
Oncotelic Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K |
| EBITDA | -3.19M | -3.55M | -7.16M | -5.60M | -9.06M |
| Net Income | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | |||||
| Total Assets | 10.00T> | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 88.86B | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 16.27T | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 10.00T> | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 10.00T> | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | |||||
| Free Cash Flow | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.39T | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Neutral
0.08
Price Trends
0.04
Negative
0.06
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
49.97
Neutral
22.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of 22.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 35 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncotelic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $44.65M | 0.10 | -225.83% | ― | -22.51% | 73.89% | |
45 Neutral | $25.21M | -2.03 | -1.04% | ― | ― | 18.69% | |
44 Neutral | $16.70M | 0.03 | -38.38% | ― | ― | ― | |
44 Neutral | $36.52M | -4.61 | -10.61% | ― | ― | 70.83% | |
40 Underperform | $9.21M | -2,298.43 | -526.36% | ― | ― | -66.83% | |
| ― | $84.33M | -3.39 | -3.76% | ― | ― | 36.74% |
* Healthcare Sector Average
OTLC
Oncotelic Therapeutics
0.04
-0.02
-33.93%
GRCE
Grace Therapeutics
2.36
-0.64
-21.33%
LTRN
Lantern Pharma
2.23
-1.44
-39.24%
CALC
CalciMedica
0.59
-1.37
-70.00%
ELUT
Elutia
1.01
-0.89
-46.84%
MAIA
MAIA Biotechnology, Inc.
1.39
-0.52
-27.23%
Oncotelic Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Oncotelic Therapeutics Posts Transformational 2025 Profit Surge
Positive
Apr 16, 2026
On April 16, 2026, Oncotelic Therapeutics reported financial results for the year ended December 31, 2025, posting net income of about $249 million versus a $4.8 million loss in 2024, largely due to a non-cash $365.4 million uplift in the fair val...
Business Operations and StrategyProduct-Related Announcements
Oncotelic forms AI-driven robotics partnership for GMP automation
Positive
Apr 2, 2026
On April 2, 2026, Oncotelic Therapeutics, Inc., a clinical-stage biotechnology company focused on oncology and AI-driven solutions, announced a strategic partnership with TechForce Robotics to commercialize an integrated PDAOAI-enabled, GMP-compli...
Business Operations and StrategyProduct-Related Announcements
Oncotelic Subsidiary Showcases Deciparticle Platform at BIO-Europe
Positive
Mar 30, 2026
On March 24, 2026, Oncotelic Therapeutics, Inc., a biotechnology company specializing in RNA-based cancer therapeutics and rare pediatric oncology, announced that its subsidiary Sapu Nano will showcase its Deciparticle nanomedicine platform at BIO...
Private Placements and Financing
Oncotelic Therapeutics Secures Convertible Debt Financing Agreement
Neutral
Jan 29, 2026
On January 23, 2026, Oncotelic Therapeutics secured $398,333 in convertible debt from Mast Hill Fund, issuing a one-year, 10% secured note convertible at $0.07 per share, together with 1,422,613 warrants at $0.15, and restricted the use of proceed...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Oncotelic Therapeutics Ties CEO Equity to Debt Milestones
Positive
Jan 26, 2026
On January 22, 2026, Oncotelic Therapeutics, Inc. entered into a restricted stock agreement with chief executive officer Dr. Vuong Trieu that ties his equity compensation to specific capital-structure improvement milestones. The company will issue...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.